SABCS 2022 | Highlights in HER2-low breast cancer at SABCS 2022

Rani Bansal, MD, Duke Cancer Center, Durham, NC, talks on what she is most looking forward to at the San Antonio Breast Cancer Symposium (SABCS) 2022 in the field of HER2-low breast cancer, including the data presented on the Phase III DESTINY-Breast06 (NCT04494425) trial, which is investigating trastuzumab deruxtecan versus investigator’s choice chemotherapy in HER2-low, HR-positive, metastatic breast cancer. DESTINY-Breast06 will demonstrate whether there is a role for trastuzumab deruxtecan in HER2-ultralow and HER2-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.